Key Points {#FPar1}
==========

Current work on genetic and molecular biomarkers for treatment response in age-related macular degeneration (AMD) is still exploratory, and precision medicine for AMD is not yet ready for implementation in the clinic.Several genetic and molecular biomarkers that associate with response to anti- vascular endothelial growth factor therapy have been identified, but these associations have not been consistently replicated.Studies on complement system biomarkers may be useful to identify patients for complement-inhibiting therapies that are currently under development.

Introduction {#Sec1}
============

Precision medicine aims to improve healthcare through individualized selection of treatment options, taking into account each patient's characteristics and individual needs. Biomarkers defining individual patient characteristics can be used in a clinical setting to define individualized screening strategies, recommend personalized preventions, select the best therapy for individual patients, tailor the dosing of medication, and can help avoid patients being given unnecessary treatments that they will not benefit from or might even be harmful. The field of precision medicine has moved forward rapidly in the last few decades thanks to the identification of genetic markers that predict response to treatment in many different diseases \[[@CR1]\]. Genetic screening prior to treatment is now increasingly being implemented in the healthcare system \[[@CR2]--[@CR4]\]. A prime example is the oncology field, where, for instance, genetic variants in the *DPYD* gene are highly recommended to be screened to avoid toxicity from fluoropyrimidine drugs \[[@CR5]\]. Other examples include the anti-coagulant warfarin, for which genotype-guided prescription has been established to improve safety and effectiveness, and to reduce healthcare costs \[[@CR6]--[@CR8]\]. Besides genetic markers, other biomarkers such as metabolites are also being explored for clinical utility in precision medicine \[[@CR9]\].

In the field of ophthalmology, the potential of precision medicine is actively being investigated. The focus of this review is age-related macular degeneration (AMD), the most common cause of blindness in the elderly in the Western world, and the third most common cause of severe visual impairment worldwide \[[@CR10], [@CR11]\]. The increased ageing of the population is boosting the number of affected individuals, which is expected to reach 196 million by 2020, therefore posing a major and rising burden on healthcare \[[@CR12]\]. AMD is a progressive disease that affects the macula, which is located in the center of the retina, and is responsible for central vision, color vision and sharp vision. In early stages, AMD is characterized by the occurrence of drusen, which are deposits of extracellular debris that accumulate underneath the retinal pigment epithelium (RPE), the cell layer supporting the neurosensory retina \[[@CR13]\]. During the course of the disease, drusen increase in number and size, and AMD can progress into advanced stages in which vision loss occurs. These advanced stages can be divided in two types: geographic atrophy (GA) and choroidal neovascularization (CNV). GA is characterized by atrophy of the retina, resulting from gradual loss of photoreceptors, RPE cells and the choriocapillaris \[[@CR14]\]. CNV, also referred to as neovascular AMD (nvAMD), involves the abnormal growth of blood vessels from the choriocapillaris invading the retina, with subsequent leakage and bleeding, and provokes a vision-threatening scar in the macula. The prevalence of both advanced types is similar, and both types of the disease cause visual loss \[[@CR12]\]; however, nvAMD accounts for most of the visual acuity loss caused by AMD \[[@CR15]\].

AMD is a complex heterogeneous disease in which genetic factors as well as environmental factors contribute to disease risk. Genetic factors play a major role in the disease etiology, explaining up to 71% of the disease variation \[[@CR16]\]. The first single-nucleotide polymorphisms (SNPs) found to be associated with AMD were rs1061170 in *CFH* and rs10490924 in *ARMS2* \[[@CR17], [@CR18]\]. In a recent genome-wide association study (GWAS), 52 independent genetic variants across 34 loci were identified to influence AMD disease risk \[[@CR19]\]. These genetic associations have implicated the complement system, lipid metabolism, extracellular matrix remodeling and angiogenesis in the disease process \[[@CR19]\]. Age is the most important demographic risk factor for AMD development, and other factors that have consistently been described to influence the disease risk are cigarette smoking, previous cataract surgery and family history of AMD \[[@CR20]\].

Currently, only advanced nvAMD can be treated, by targeting vascular endothelial growth factor (VEGF). For GA, although several therapies are actively being developed, no established treatment is available to date. Also, progression of the disease cannot be halted, but it can be slowed down with the use of nutritional supplements.

Due to the heterogeneity in the AMD patient population, it is plausible that the effect of therapeutic interventions depends on the biological drivers of disease in each individual patient. In essence, the patient's genetic blueprint, in addition to demographic and lifestyle factors, is likely to influence how a patient responds to treatment. Consequently, the identification of biomarkers that can predict response to therapy in AMD could be used to improve AMD patient care, by tailoring medication to each patient's individual needs.

In this review, we aim to provide an overview of the current literature investigating the association of biomarkers with response to supplements and anti-VEGF therapy, as well as to describe new therapeutic approaches undergoing clinical trials and the potential use of biomarkers for patient selection.

Current Therapeutic Interventions for Age-Related Macular Degeneration Management {#Sec2}
=================================================================================

Dietary Supplements for Slowing Disease Progression {#Sec3}
---------------------------------------------------

Dietary supplementation with vitamins and zinc is proven to reduce the risk of progression to advanced AMD. These supplements act against oxidative stress, which is thought to be one of the drivers of AMD pathogenesis \[[@CR21], [@CR22]\]. Oxidative stress refers to a disturbance in the balance between the production of reactive oxygen species and antioxidant defenses. The retina is highly susceptible to oxidative stress due to sunlight exposure, high oxygen consumption and high concentration of polyunsaturated fatty acids. Moreover, oxidative stress increases with age and is associated with smoking, another AMD risk factor \[[@CR22]\]. The notion that oxidative stress may play an important role in AMD development and progression led to the development of the Age-Related Eye Disease Study (AREDS) clinical trial that evaluated the effect of high doses of vitamin C, vitamin E, beta-carotene and zinc on AMD progression. In 2001, the AREDS trial concluded that patients with intermediate AMD in at least one eye receiving this formulation reduced their risk of progression to advanced AMD by 25% at 5 years \[[@CR23]\]. An AREDS 2 supplementation trial followed in 2013, describing an improved formula with lutein and zeaxanthin substituting beta-carotene. This formula showed the same effects, but is preferred as beta-carotene conferred risk for lung cancer in former smokers \[[@CR24]\]. Clinicians have rapidly adopted the AREDS recommendations, and the oral use of antioxidants combined with zinc is currently prescribed for intermediate or unilateral advanced AMD.

AMD-associated variants have been found to influence AMD progression, and for several years, there have been investigations into whether specific genotypes interact with the AREDS supplementation, affecting progression rates \[[@CR25]\]. These studies sparked an intense debate in the field as different research groups arrived at different conclusions. In 2008, Klein et al. suggested that response to AREDS supplements could be related to the *CFH* rs1061170 genotype \[[@CR26]\]. The study evaluated 876 AREDS patients and found that for carriers of the CC genotype, dietary supplementation would have a smaller effect, possibly related to zinc consumption, but would still be beneficial. No interaction was found for the *ARMS2* rs10490924 SNP. In 2013, a second study that included 995 AREDS participants was published by Awh et al., also proposing a genotypic interaction \[[@CR27]\] and suggesting that improved outcomes could be obtained after genotype selection. The authors described a deleterious interaction between *CFH* risk alleles (rs412852 and rs3766405) and supplementation with zinc, in which carriers of *CFH* risk alleles would progress to advanced AMD faster when taking zinc. Also, the authors claimed that individuals homozygous for the *CFH* and *ARMS2* risk alleles would not benefit from the AREDS formula. After these results, the AREDS Research Group attempted replication in a larger AREDS cohort of 1237 AMD patients, but did not identify any interaction, and concluded that reduction in the risk of AMD progression after supplementation was seen in all genotype groups \[[@CR28]\]. This study was followed by a series of contradictory results \[[@CR29]--[@CR31]\] and intense argumentation \[[@CR32]--[@CR34]\]. In a recent report, independent statistical research groups analyzed the data from the AREDS Research Group and from Awh and colleagues. Errors in the Awh et al. 2013 study were noted, and no interaction was reported between the *CFH* and *ARMS2* SNPs and treatment response after correction for multiple testing. Therefore, it was concluded that AMD patients should be offered dietary supplementation regardless of genotype \[[@CR35]\]. The most recent study performed multiple statistical analyses on an extended AREDS dataset of 802 individuals and suggested that the response to AREDS formulation treatment varies substantially among individuals, based on *CFH* and *ARMS2* genotypes. This study therefore concludes that the use of the AREDS formulation should be based on patient-specific genotypes \[[@CR36]\].

Anti-VEGF Antibodies for Choroidal Neovascularization Treatment {#Sec4}
---------------------------------------------------------------

The gold-standard treatment for nvAMD consists of intravitreal injections of anti-VEGF antibodies. VEGFA is the master regulator of angiogenesis and leads to proliferation, migration and survival of vascular endothelial cells, as well as to vascular permeability \[[@CR37], [@CR38]\]. In the AMD disease process, hypoxia, oxidative stress and activation of the complement system promote VEGFA secretion by the RPE, which will eventually lead to abnormal CNV formation \[[@CR39]--[@CR41]\]. Anti-VEGF antibodies block VEGFA binding to its receptors and thus inhibit its angiogenic effects.

Anti-VEGF antibodies for nvAMD treatment include ranibizumab (Lucentis; Novartis, Basel, Switzerland, and Genentech Inc., South San Francisco, USA), bevacizumab (Avastin, Genentech, South San Francisco, USA), and aflibercept (EYLEA, Regeneron Pharmaceutical Inc., Tarrytown, USA). Bevacizumab has been approved by the Food and Drug Administration (FDA) for the treatment of several cancer types; however, it is administered off label for the treatment of nvAMD. The CATT and IVAN clinical trials demonstrated similar outcomes after bevacizumab treatment compared to ranibizumab \[[@CR42]--[@CR45]\]. The administration of these agents usually consists of a loading dose of three monthly injections followed-up with a variable treatment regimen.

The use of anti-VEGF drugs to treat nvAMD has significantly changed the prognosis of the disease and has led to significant improvements in visual acuity. Nevertheless, a more detailed analysis of individual patient outcomes shows that not all patients benefit equally from the therapy. Vision remains stable or improves in approximately 80% of the patients, but approximately 20% of treated patients continue to lose vision despite treatment \[[@CR46], [@CR47]\]. Along the same line, anatomical changes in the retina after treatment, reflecting fluid clearance, are also variable among patients \[[@CR42]\].

Understanding the reasons underlying this variability in treatment outcome can help improve treatment strategies, would allow early identification of poor responders, and would enable individual treatment optimization. Clinical and epidemiological factors that have repeatedly been associated with worse treatment outcome include baseline parameters such as older age, larger CNV lesion, larger retinal tissue thickness and lower visual acuity \[[@CR48]\]. These factors are highly correlated and indicative of longer disease duration, highlighting the importance of initiating treatment in an early phase. Nevertheless, these factors cannot fully explain the wide range in treatment outcomes \[[@CR49]\]. Due to the highly heritable nature of AMD, it has been hypothesized that genetic factors may influence treatment outcome. Genetic markers are independent of disease duration and therefore may explain treatment outcome variability.

Since the first publication in 2007 \[[@CR50]\], a vast number of studies have investigated associations of genetic variants with anti-VEGF treatment outcome in nvAMD. We reviewed the pharmacogenetic studies published to date and provide a detailed overview of their study designs and conclusions in Table [1](#Tab1){ref-type="table"}. Despite the large body of literature on this topic, with over 50 studies published, solid conclusions cannot be drawn. This is due to conflicting results and a high heterogeneity in study designs, which makes comparisons between studies challenging. Studies may involve ranibizumab treatment, bevacizumab treatment or both. Moreover, the definition of treatment response is highly variable: change in visual acuity, change in total retinal thickness, CNV recurrence or number of injections are some of the variables used to measure treatment outcome. These variables are analyzed in a continuous or in a categorical manner, in which responders are compared to non-responders based on an arbitrary definition of response. Additionally, the studies evaluate response after the loading dose of three monthly injections or longer and may therefore involve different treatment protocols. Also, correction for multiple testing is not applied in all studies, and the majority of studies do not provide a statistical power calculation.Table 1Overview of pharmacogenetic studies for anti-VEGF treatment of neovascular AMDReferences*N* ^a^Ethnicity/country of originDesignAnti-VEGFTreatment regimenTreatment outcome definition(s)Gene: SNPsConclusionBrantley et al. \[[@CR50]\]86CaucasianRBVZ6-weekly inj. until no active CNVVA after at least 6 months of treatment*CFH*: rs1061170\
*ARMS2*: rs10490924\
*CFH *+ *ARMS2*: rs1061170 + rs10490924*CFH* rs1061170 CC → worse responseLee et al.\[[@CR51]\]156CaucasianRRNZPRNVA after 6, 9 months\
*N* of inj. after 9 months\
Interval between required inj. after 9 months\
Interval between follow-up appointments after 9 months*CFH*: rs1061170*CFH* rs1061170 CC → worse responseTeper et al. \[[@CR64]\]90CaucasianPRNZ3 monthly inj. + SUSTAIN criteriaChange in VA after 12 months\
Change in CSRT after 12 months\
*N* of inj. after 12 months*CFH*: rs1061170\
*ARMS2*: rs10490924*ARMS2* rs10490924 TT → worse responseImai et al.\[[@CR52]\]83JapaneseRBVZ1 inj. + retreatment after recurrence of AMDResponders vs. non-responders: responders if improvement in VA after 1, 3 months\
Change in CRT after 1, 3 months\
CNV recurrence after 1, 3 months*CFH*: rs800292, rs1061170, rs1410996\
*HTRA1*: rs11200638\
*VEGFA*: rs699947, rs1570360, rs2010963\
*PEDF*: rs12150053, rs12948385, rs9913583, rs1136287*CFH* rs1061170 CT → worse response than TT\
*VEGFA* rs699947 C → worse response\
*PEDF* rs1136287 → not describedNakata et al. \[[@CR152]\]94NI (Japan)RBVZ1--3 inj., when remnant exudative changes 2nd and or 3rd inj. monthlyVA after 12 months\
Change in VA after 12 months\
*N* of inj. after 12 months\
*N* of recurrences after 12 months\
Periods until recurrence after 12 months*VEGFA*: rs699946, rs699947*VEGFA* rs69946 A → worse responseNischler et al. \[[@CR53]\]197NI (Austria)PBVZ1 inj. + 6-weekly until no active CNV*N* of treatments\
CMT after treatment\
VA after treatment\
Reading VA after treatment\
Gain or loss of ≥ 3 lines in distance VA\
Gain or loss of ≥ 3 lines in reading VA*CFH*: rs1061170*CFH* rs1061170 CC → worse responseWickremasinghe et al. \[[@CR92]\]168CaucasianRRNZ or BVZ and RNZNo specific retreatment strategies (75% 3 monthly inj.)Improved: 2-line gained in VA; stable: VA within 2 lines of baseline; or decreased: reduction in VA of 2 lines or more*APOE*: ε2, ε3 and ε4*APOE* ε4 allele → better responseFrancis et al. \[[@CR95]\]44CaucasianPRNZMonthly "as needed"Change in letters after 12 monthsGWAS: Illumina 660-Quad SNP array: \> 480,000 SNPsCandidate gene analysis:\
*CFH* rs1065489 AA → worse responseKloeckener-Gruissem et al. \[[@CR54]\]243 eyes, 215 individualsNI (Switzerland)RRNZPRNChange in VA after 12 months, poor responders: ≤ 25th percentile; good responders: ≥ 75th percentile*CFH*: rs1061170\
*FZD4*: rs10898563*CFH* rs1061170 CC → worse response\
*CFH* rs1061170 CT and *FZD4* rs10898563 AG → better responseWang et al. \[[@CR153]\]106CaucasianNIBVZ/RNZ1 inj. + PRN for 12 monthsPoor responder (based on VA, and OCT parameters)21 SNPs in *IL23*, *PLA2G12A*, *HIF1A*, *STAT3*, *VEGF*, *KDR*No associations found (after correction for multiple testing)McKibbin et al. \[[@CR65]\]104CaucasianRRNZ3 monthly inj. + PRNGain of \> 5 letters vs. rest after 6 months\
Change in VA after 6 months*CFH*: rs1061170\
*HTRA1*: rs11200638\
*VEGFA*: rs1413711No association found (after correction for multiple testing)Orlin et al. \[[@CR66]\]150NI (USA)RBVZ/RNZ3 monthly inj. + TEAfter last visit, positive responders: improvement or no change in VA; negative responders: loss of VA or final VA 20/200*CFH*: rs1061170\
*ARMS2*: rs10490924, rs3750848, del443ins54\
*HTRA1*: rs3793917, rs11200638, rs932275No associations foundSmailhodzic et al. \[[@CR55]\]420 eyes, 397 individualsNI (the Netherlands, Germany, Canada)RRNZ3 monthly inj. + PRNChange in VA after 3 months*CFH*: rs1061170\
*ARMS2*: rs10490924\
*VEGFA*: rs699947, rs833069\
*KDR*: rs2071559, rs7671745\
*LPR5*: rs3736228\
*FZD4*: rs10898563\
*CFH *+ *ARMS2*: rs1061170 + rs10490924\
*CFH *+ *ARMS2 *+ *VEGFA*: rs1061170 + rs10490924 + rs699947*CFH* rs1061170 TT → better response\
*CFH *+ *ARMS2* 0 risk alleles → better response\
*CFH *+ *ARMS2* 1 or 2 risk alleles → older age at first inj.\
*CFH *+ *ARMS2 *+ *VEGFA* less risk alleles → better responseBoltz et al. \[[@CR154]\]185 eyes, 141 individualsNI (Germany)PBVZPRN for 42--182 daysMean change in VA after treatment\
*N* of treatments after treatment\
Duration of the treatment*VEGFA*: rs1413711, rs3025039, rs2010963, rs833061, rs699947, rs3024997, rs1005230No associations foundMenghini et al. \[[@CR56]\]204 eyes, 194 individualsNI (Switzerland)RRNZ3 monthly inj. + PRN or PRNAfter 12, 24 months, good responders: ≥ 5-letter improvement; poor responders: ≥ 5-letter loss*CFH*: rs1061170*CFH* rs1061170 CT → better response\
*CFH* rs1061170 CT/TT → better responseTian et al. \[[@CR67]\]144ChinesePBVZ6-weekly inj.Change in letters after 3 months\
Change in CRT after 3 months\
Maximum lesion thickness after 3 months*CFH*: rs800292, rs1061170, rs10801555, rs1410996\
*ARMS2*: rs10490924\
*HTRA1*: rs11200638\
*VEGFA*: rs833069, rs3025039\
*SERPING1*: rs1005510, rs2511989\
*C3*: rs2230205, rs2250656*CFH* rs800292 CC → worse response\
*ARMS2* rs10490924 TT → worse response\
*HTRA1* rs11200638 AA → worse responseKang et al. \[[@CR57]\]75KoreanRBVZ3 monthly inj. + PRN for 6 months/12 monthsChange in VA after 3, 6, 12 months\
Change in CRT after 3, 6, 12 months\
*N* of additional inj. after loading dose*CFH*: rs1061170\
*ARMS2*: rs10490924\
*HTRA1*: rs11200638*ARMS2*: rs10490924 G → worse response\
*CFH* rs1061170 TC → worse response than TTLazzeri et al. (2013)64ItalianPRNZ3 monthly inj.Change in letters after 3 months*VEGFA*: rs699947, rs1570360*VEGFA* rs699947 C → better responseDikmetas et al. \[[@CR58]\]193TurkishRRNZPRNAt final examination, good response: ≥ 5 letters; bad response: decrease of ≥ 5 letters; very good response: ≥ 15 letters; very bad response: decrease in VA of ≥ 15 letters*CFH*: rs1061170*CFH* rs1061170 C → worse responseChang et al. \[[@CR68]\]102KoreanRRNZ3 monthly inj. + PRNChange in VA after 3, 6 months\
Change in CSMT after 3, 6 months*CFH*: rs1061170\
*ARMS2*: rs10490924\
*HTRA1*: rs11200638\
*VEGFA*: rs833069\
*KDR*: rs2071559*VEGFA* rs833069 G → better responseKitchens et al. \[[@CR69]\]101NI (USA)RBVZ/RNZ3 monthly inj. + PRN for 6 months/12 monthsBased on OCT, responder: no fluid after inj. for after least 1 month; non-responder: fluid present 1 month after the 3rd inj.\
Based on VA, responder: gained ≥ 3 lines after month 9; non-responder: no gain of ≥ 3 lines after month 9*CFH*: rs1061170\
*ARMS2*: rs10490924\
*VEGFA*: rs699947, rs1570360, rs833060, rs36208049, rs833061, rs25648, rs59260042, rs2010963*ARMS2* rs10490924 TT → worse responseAbedi et al. \[[@CR70]\]224CaucasianPBVZ/RNZ3 monthly inj. + PRNChange in VA after 12 months*CFH*: rs800292, rs3766404, rs1061170, rs2274700, rs393955\
*HTRA1*: rs11200638\
*CFHR1--5:* rs10922153, rs16840639, rs6667243, rs1853883\
*ARMS2*: rs3793917, rs10490924\
*C3*: rs2230199, rs1047286\
*C2*: rs547154\
*CFB*: rs641153\
*F13B*: rs6003*HTRA1* rs11200638 AA → worse response\
*ARMS2* rs10490924 TT → worse responseHagstrom et al. \[[@CR71]\]834CATT (98% Caucasian), NIPBVZ/RNZPRN/monthlyVA after 12 months\
Change in VA after 12 months\
Proportion of patients with ≥ 15-letter increased after 12 months\
Proportion of patients with a thin (\< 120 µm), normal (120--212 µm) and thick (\> 212 µm) retina after 12 months\
Change in TFT after 12 months\
*N* of inj. after 12 months*CFH*: rs1061170\
*ARMS2*: rs10490924\
*HTRA1*: rs11200638\
*C3*: rs2230199No associations foundAbedi et al. \[[@CR155]\]201CaucasianPBVZ/RNZ3 monthly inj. + PRN for 12 monthsChange in VA after 3, 6, 12 months\
Responder vs. non-responder or stable for *VEGFA* rs3025000 at 12 months*VEGFA*: rs3024994, rs3025000, rs3025042, rs3025047, rs3025035, rs3025030, rs3025010*VEGFA* rs3025000 T → better responseLotery et al. \[[@CR72]\]509IVAN, NIPBVZ/RNZ3 monthly inj. + PRN/monthlyChange in TRT after 12 months or the preceding measurement nearest to this time point; responders ≥ 75th percentile; non-responders ≤ 25th percentile*CFH*: rs1061170\
*FZD4*: rs10898563\
*ARMS2*: rs10490924\
482 additional SNPs in candidate genesNo associations found (after correction for multiple testing)Hautamäki et al. \[[@CR73]\]96NI (Finland)R (59), from a P study (37)BVZ3 inj. within 5 monthsResponder, partial responder or non-responder based on neuroepithelial detachment, cystic changes and area of cysts*IL8*: rs4073\
*CFH*: rs1061170\
*ARMS2*: rs10490924\
*C3*: rs2230199\
*VEGFA*: rs699947, rs2146323, rs3025033\
*EPO*: rs1617640*IL8* rs4073 A → worse responseHabibi et al. \[[@CR74]\]70TunisianPBVZ6-weekly inj. until non-active CNVImprovement in VA: 2-line gain after 6 months; stable vision: VA within 2 lines of baseline; decrease: reduction in VA of 2 lines or more*CFH*: rs1061170No association foundZhao et al. \[[@CR156]\]223 eyes, individuals NICaucasianPBVZ/RNZ4 monthly inj. + PRNResponders: ≥ 5 letters and resolution of intraretinal or subretinal fluid after 12 months; non-responders: rest of the patients*VEGFA*: rs943080*VEGFA* rs943080 T → worse responseYuan et al. \[[@CR75]\]168Han ChinesePRNZ3 monthly inj. + PRNChange in VA after 6 months\
Change in CRT after 6 months\
Change in maximum lesion thickness after 6 months*CFH*: rs1061170\
*HTRA1*: rs11200638\
*VEGFA*: rs1413711*HTRA* rs11200638 A → worse responseHagstrom et al. \[[@CR157]\]831CATT (98% Caucasian), NIPBVZ/RNZPRN/monthlyChange in TRT after the latest time point for which data were available through 1 year; responders: ≥ 75th percentile; non-responders: ≤ 25th percentile*EPAS1*: rs6726454, rs7589621, rs9679290, rs12712973No associations foundHermann et al. \[[@CR158]\]366NI (the Netherlands, Germany, Canada)NIRNZ3 monthly inj. + PRNChange in VA after 3, 12 months126 SNPs in *VEGFA*, *VEGFB*, *VEGFC, VEGFD*, *PGF*, *VEGR1*, *VEGFR2*, *VEGFR3*, *PEDFKDR* rs4576072 C → better response\
*KDR* rs4576072 (C) and rs6828477 (C) 3 alleles → better responseHagstrom et al. \[[@CR159]\]835CATT (98% Caucasian), NIPBVZ/RNZ3 monthly inj. + PRN/monthlyVA after 12 months\
Change in VA after 12 months\
TRT after 12 months\
Change in TFT after 12 months\
Presence of fluid on OCT\
Presence of leakage on FA after 12 months\
Change in lesion size after 12 months\
*N* of inj. after 12 months*VEGFA*: rs699947, rs699946, rs833069, rs833070, rs1413711, rs2010963, rs2146323\
*KDR*: rs2071559 \
*N* of risk allelesNo associations foundCruz-Gonzalez et al. \[[@CR160]\]94CaucasianPRNZ3 monthly inj. + SUSTAIN criteriaSubjective improvement: patients measure their improvement after each inj. on a scale from 1 to 10, Subjective improvement ≥ 6\
VA improvement: gain ≥ 5 letters\
OCT improvement: improvement \> 100 μmin in central subfield retinal thickness*VEGFA*: rs699947, rs833061\
*KDR*: rs2071559*VEGFA* rs8330611 CC → better response\
*VEGFA* rs699947 AA → better responseMatsumiya et al. \[[@CR84]\]120JapaneseRRNZ3 monthly inj.Anatomical resolution of the lesions after 3 months\
Dry lesion in OCT/no exudative lesion\
Change in VA after 3 months\
Change in CRT after 3 months*CFH*: rs1061170, rs800292\
*HTRA1*: rs10490924\
*CFH*: rs1061170 + rs800292*CFH* rs1061170 TT + rs800292 GG → worse responsePark et al. \[[@CR78]\]273KoreanPRNZ5 monthly inj.Good response after month 5: visual improvement of ≥ 8 letters23 SNPs in 12 AMD genesNo associations found (after correction for multiple testing)Veloso et al. \[[@CR161]\]92BrazilianPRNZ3 monthly inj. + PRNChange in VA after 1, 3, 6 and 12 months\
Change in CRT after 1, 3, 6 and 12 months*VEGFA*: rs1413711*VEGFA* rs1413711 CC → worse responseHautamäki et al. \[[@CR59]\]50CaucasianPBVZPRNChange in CS after 24 months\
Presence of intra/subretinal fluid in OCT after 24 months\
*N* of inj. after 24 months*IL8*: rs4073\
*VEGFA*: rs699947, rs2146323, rs3025033\
*CFH*: rs1061170\
*ARMS2*: rs10490924\
*C3*: rs2230199\
*IL8* rs4073 + *VEGF* rs699947 + *CFH* rs1061170*VEGFA* rs699947 AA → worse response\
*ARMS2*: rs10490924 TT → worse response\
*IL8*: rs4073 AA → worse response\
*CFH* rs1061170 CC → worse response\
*IL8* rs4073 A + *VEGF* rs699947 A + *CFH* rs1061170 C 3--6 risk alleles → worse responsePiermarocchi et al. \[[@CR60]\]94CaucasianPRNZ3 monthly inj. + PRNChange in VA after 12 months*CFH*: rs1061170\
*ARMS2*: rs10490924\
*C3*: rs2230199*CFH* rs1061170 C → worse responseMedina et al. \[[@CR61]\]25BrazilianPBVZ1 inj.Improvement in VA and CRT is evaluated separately per genotype. Results are compared*CFH*: rs1061170*CFH* rs1061170 CC → worse responseHagstrom et al. \[[@CR162]\]1347CATT and IVAN, NIPBVZ/RNZPRN/monthlyChange in VA after 12 months*KDR*: rs4576072, rs6828477 \
*N* of risk alleles in *KDR* rs4576072 + rs6828477No associations foundKuroda et al. \[[@CR85]\]343 eyes, 326 individualsJapaneseRRNZ3 monthly inj. + PRNRecurrence after 12 months\
Change in VA after 12 months*CFH*: rs1410996\
*ARMS2*: rs10490923No associations foundLorés-Motta et al. \[[@CR91]\]377NI (the Netherlands, Germany, Canada)RRNZ3 monthly inj. + PRN/TEChange in VA after 3, 6 and 12 months*NRP1*: rs2070296 \
*N* of risk alleles in *KDR* rs4576072 + *NRP1* rs2070296*NRP1* rs2070296 GA and AA → worse response\
3, 4, 5 risk alleles in *KDR* rs4576072 + *NRP1* rs2070296 → worse responseBakbak et al. \[[@CR93]\]109TurkishPRNZ3 monthly inj. + PRNAfter 6 months, loss \> 5 letters, loss or gain of VA between 5 letters or gain \> 5 letters*APOE*: ε2, ε3 and ε4*APOE* ε4 allele → better responseLazzeri et al. \[[@CR94]\]64NI (Italy)PRNZ3 monthly inj. + PRNVA after 3, 12 months\
Retinal sensitivity after 3, 12 months\
TFT after 3, 12 months\
*N* of inj. in the follow-up phase*KDR*: rs2071559\
*IL8*: rs4073*IL8* rs4073 AA → worse response\
*KDR* rs20715559 CC → better responseCruz-Gonzalez et al. \[[@CR86]\]100CaucasianPRNZ3 monthly inj. + PRNVA improvement: gain ≥ 5 letters\
OCT improvement: gain \> 100 µm in CSRT*CFH*: rs1410996\
*ARMS2*: rs10490923\
*HTRA1*: rs11200638No associations foundRiaz et al. \[[@CR96]\]661 (discovery: 285, replication: 376)NI (Australia, the Netherlands, Germany, Canada)RRNZ3 monthly inj. + PRN/TEChange in VA in after 3, 6 months; non-responder: lose ≥ 5 letters; responder: restGWAS: Illumina 4.3 M SNP array: \> 1,000,000 SNPs*OR52B4* rs4910623 G → worse responseHabibi et al. \[[@CR76]\]90TunisianRBVZ3 monthly inj. + PRNAfter 12 months, good responder: reduction of \< 2 lines; poor responder: reduction of ≥ 2 lines*CFH*: rs1061170\
*C3*: rs2230199\
*VEGFA*: rs2010963, rs3025039, rs699947 \
*N* of risk alleles in *CFH*, *C3* and *VEGFA*\
*VEGFA* haplotypes*VEGFA* haplotype rs2010963 G, rs3025039 T, rs699947 A → worse responseChaudhary et al. \[[@CR87]\]70Caucasian (68), Asian (2)PRNZ3 monthly inj. + PRNModerate vision gain: gain of ≥ 15 letters after 6 months\
Change in CMT after 6 months\
Change in VA after 6 months*CFH*: rs1048663, rs3766405, rs412852, rs11582939, rs1066420\
*C3*: rs2230199\
*ARMS2*: rs10490924\
mtDNA: A2917G\
*CFH* haplotypes*CFH* haplotype that reduces risk to AMD leads to better responseKepez Yildiz et al. \[[@CR99]\]109TurkishRNI3 monthly inj.Good responder group and non-responder group based on VA and OCT parameters after 3 months*CFH*: rs1061170\
*VEGFA*: rs2146323, rs699947No associations foundShah et al. \[[@CR62]\]72NI (USA)RBVZ/RNZPRNChange in VA after 6, 12 months\
Change in central foveal thickness after 6, 12 months20 SNPs in AMD genes\
*N* of risk alleles in *CFH* rs1061170 and rs1410996\
Number of risk alleles for *CFI* rs10033900 and *CFI* rare variants*CFH* rs1061170 TT → better response\
0--2 risk alleles in *CFH* rs1061170 and rs1410996 → better responseBardak et al. \[[@CR163]\]39NI (Turkey)RRNZ3 monthly inj.Responders: absence of intraretinal or subretinal fluid; non-responder: presence. Comparisons for each genotype*ARMS2*: rs10490923*ARMS2* rs10490924 TT shows differences in responseValverde-Megías et al. \[[@CR77]\]103CaucasianPRNZ3 monthly inj. + PRN*N* of inj. after 4 years*CFH*: rs1061170\
*ARMS2*: rs10490924*ARMS2* rs10490924 TT → worse responseYamashiro et al. \[[@CR83]\]461 (discovery: 256, replication: 205)NI (Japan)PRNZ3 monthly inj. + PRNDry macula after treatment\
Requirement for an additional treatment\
VA changes after 12 monthsGWAS: Illumina HumanOmni2.5--8 BeadChip Kit. Imputation followed: \> 8,400,000 SNPsNo genome-wide level significant associations\
No associations with *P* \< 5 × 10^−6^ replicated\
9 candidate SNPs:\
*ARMS2*: rs10490924 G → better responseMedina et al. \[[@CR63]\]46BrazilianRBVZ/RNZPRNBaseline and 12 months VA and CRT compared for each genotype separately*CFH*: rs1061170*CFH* rs1061170 C → worse response*AMD* age-related macular degeneration, *BVZ* bevacizumab, *CMT* central macular thickness, *CNV* choroidal neovascularization, *CRT* central retinal thickness, *CS* contrast sensitivity, *CSMT* central subfield macular thickness, *CSRT* central subfield retinal thickness, *QWAS* genome-wide association study*, inj.* injection(s), *letters* early treatment diabetic retinopathy study letters, *N* number, *NI* not indicated, *OCT* optical coherence tomography, *P* prospective, *PRN* pro re nata, *R* retrospective, *RNZ* ranibizumab, *SNP* single-nucleotide polymorphism, *TE* treat-and-extend, *TFT* total foveal thickness, *VA* visual acuity^a^Used for analysis

At the onset of the field of pharmacogenetics in AMD, a natural target to explore was the main genetic variant associated with AMD: SNP rs1061170 in the *CFH* gene. Indeed, most of the studies have investigated this SNP; however conflicting results have been reported. Several studies have reported an association of this genetic variant with response to anti-VEGF treatment \[[@CR50]--[@CR63]\]; in all instances, the AMD-risk-conferring allele (C) led to a worse outcome after therapy. However, others have not identified any association \[[@CR64]--[@CR78]\]. Three different meta-analyses have been carried out, all showing an association of rs1061170 with treatment response with a moderate level of significance \[[@CR79]--[@CR81]\]. The most recent and comprehensive study included a total of 2963 individuals from 14 different studies and showed that patients homozygous for the AMD low-risk allele (T) were more likely to have a better outcome compared to patients homozygous for the AMD high-risk allele (C) \[odds ratio (OR) = 1.932, 95% confidence interval (CI) 1.125--3.173, *P* = 0.017\] \[[@CR81]\]. Notably, the two studies based on the IVAN and CATT clinical trials did not find any association for this variant, nor for any other variant investigated, despite their large sample sizes (*n* = 834 and *n* = 509, respectively) \[[@CR71], [@CR72]\].

The SNPs in *ARMS2/HTRA1* (rs10490924 and rs11200638, which are in high linkage disequilibrium) \[[@CR82]\] have also been widely evaluated for association with treatment outcome. A similar scenario emerged for these SNPs, where several studies reported an association in which the AMD-risk allele leads to worse response \[[@CR59], [@CR64], [@CR67], [@CR69], [@CR70], [@CR75], [@CR77], [@CR83]\], while others do not report an association \[[@CR50], [@CR52], [@CR59], [@CR60], [@CR62], [@CR65], [@CR68], [@CR71]--[@CR73], [@CR78], [@CR84]--[@CR87]\]. As an exception, Kang and colleagues described that carriers of the AMD-risk allele in rs10490924 needed fewer bevacizumab injections after the loading dose \[[@CR57]\]. A meta-analysis including 2389 cases from 12 studies showed that patients homozygous for the AMD low-risk allele in *ARMS2* rs10490924 (GG) have a higher chance of responding better to treatment compared to patients heterozygous (TG) or homozygous (TT) for the AMD high-risk allele (OR = 1.34, 95% CI 1.01--1.77, *P* = 0.039), although no significant difference was found on the allele level. Also, no differences were found when the analysis was limited to patients of European descent \[[@CR88]\]. Another meta-analysis of 1570 cases from five studies showed no association for the SNP rs11200638 \[[@CR89]\]. Most study designs evaluated treatment outcome after 3--12 months of treatment, but a recent study evaluated the effect of genetic variants after 4 years of anti-VEGF treatment. This study by Valverde-Megías et al. examined the rs1061170 *CFH* and rs10490924 *ARMS2* SNPs and reported that patients homozygous for the AMD-risk allele of the *ARMS2* SNP required more injections over this long-term follow-up period \[[@CR77]\].

Due to the nature of anti-VEGF therapy, the *VEGFA* gene and the *KDR* gene, encoding the main receptor for VEGFA, were also considered candidates to be involved in anti-VEGF treatment response. Most of the SNPs investigated in these genes have recently been evaluated in a meta-analysis. After evaluation of nine SNPs (rs699947, rs699946, rs833069, rs833061, rs2146323, rs1413711, rs2010963 and rs1570360 in *VEGFA*, and rs2071559 in *KDR*), anti-VEGF treatment was found to be more effective in patients homozygous for the *VEGFA* rs833061 minor allele C, compared to the remaining AMD patients (OR = 2.362, 95% CI 1.41--3.95, *P* = 0.001). This analysis was, however, limited in sample size, including only 444 AMD patients from three independent studies \[[@CR90]\]. An SNP (rs2070296) in the neuropilin-1 (*NRP1*) gene, encoding the co-receptor for VEGF, has been associated with worse response to treatment in one study \[[@CR91]\], but this SNP has not yet been evaluated in independent cohorts. Other reported associations with treatment response include the *APOE* ε4 allele \[[@CR92], [@CR93]\], *IL8* rs4073 \[[@CR59], [@CR73], [@CR94]\], and *PEDF* rs1136287 \[[@CR52]\], which have been analyzed in only a limited number of studies and warrant replication analyses.

The aforementioned variants have been examined in candidate gene/variant studies because of their known role in AMD or the neovascularization process. In contrast, GWASs examine genetic variation across the whole genome in a hypothesis-free approach. Three GWASs for anti-VEGF treatment response have been published to date \[[@CR83], [@CR95], [@CR96]\]. The first study, by Francis, involved only 65 AMD patients. When evaluating only candidate genes, an association with visual acuity outcome was reported for *CFH* rs1065489, and an association with change in macular thickness was reported for *C3* rs2230205 \[[@CR95]\]. In the second study, Riaz and colleagues included a total of 673 AMD patients and, after replication in an independent cohort, described rs4910623 located in the olfactory receptor gene *OR52B4* as a new variant associated with worse treatment outcome \[[@CR96]\]. The last study by Yamashiro et al. analyzed 461 AMD patients collected in a prospective study design, and in a discovery and replication setting. The discovery GWAS phase in 256 patients did not identify any genome-wide associations, and suggestive associations could not be replicated. In a candidate SNP analysis that included nine variants, *ARMS2* rs10490924 G was associated with additional treatment requirement after the loading dose \[[@CR83]\].

In addition to the pharmacogenetic studies, other biomarkers have also been described to be associated with anti-VEGF treatment response in nvAMD. In aqueous humor, VEGF and interleukin-6 (IL-6) levels have been measured prior to treatment, and they seem to be indicative of the outcome. Lai and colleagues reported that baseline aqueous VEGF levels associated with persistent angiographic leakage after 3 months of bevacizumab therapy \[[@CR97]\]. In another study, by Chalam and colleagues, correlations of VEGF and IL-6 levels with change in central subfield macular thickness after three monthly injections of bevacizumab treatment were described, with the correlation of IL-6 levels being the strongest \[[@CR98]\].

Studies in plasma and serum have also suggested potential systemic biomarkers. Kepez Yildiz et al. described higher levels of plasma IL-6 in good responders compared to non-responders \[[@CR99]\]. Nassar and colleagues evaluated 16 inflammatory cytokines and found that high IL-17 and tumor necrosis factor-α (TNF-α) serum levels were associated with favorable response to anti-VEGF therapy \[[@CR100]\]. Lechner et al. described that plasma complement component (C3a) levels were elevated in partial responders compared to complete responders; no differences were found for C4a and C5a levels \[[@CR101]\]. Additionally, Kubicka-Trząska and colleagues analyzed serum anti-retinal antibodies and reported that a decrease in anti-retinal antibodies levels after bevacizumab treatment correlated with functional and anatomical response \[[@CR102]\].

Therapies in Clinical Trials {#Sec5}
============================

Complement-Inhibiting Therapies {#Sec6}
-------------------------------

Anti-VEGF treatment is currently only indicated for nvAMD, which affects only half of the advanced AMD patients. For the other half, who suffer from GA, no treatment is available yet. Current research and development efforts are heavily focused on this category of patients, and genetic and physiological associations are used to identify targets for therapy. Based on this, a prime candidate target in AMD is the complement system, an essential component of the immune system. The complement system consists of an intricate proteolytic cascade that leads to inflammation, opsonization and targeted cytolysis through the formation of the membrane attack complex (MAC) (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR103]\]. Over-activation of the complement system, particularly of the alternative pathway, has been described to be associated with AMD \[[@CR104]\]. Consequently, several therapies aiming to inhibit complement activity are being developed. These therapies aim to slow down disease progression and to prevent the development of GA, but may also be useful for nvAMD patients in combination with anti-VEGF drugs.Fig. 1Schematic representation of the complement system proteolytic cascade. **a** Complement-inhibiting therapies currently evaluated in clinical trials and their specific targets are presented. The targets of the complement-inhibiting therapies are complement C3, complement factor D (FD), complement C5, properdin and CD59. C3 is a central component of the complement cascade, as upon activation, its cleavage leads to the formation of the anaphilatoxin C3a and to the opsin C3b. C3b will also form the alternative pathway C3 convertase and all C5 convertases. FD activates the system through the cleavage of C3b-bound FB to form the alternative pathway convertases. C5 is the second central component of the cascade downstream of C3. Upon cleavage, C5 leads to the anaphylatoxin C5a and to C5b, the first component of the membrane attack complex (MAC). Properdin is a positive regulator of the system that stabilizes the alternative pathway convertases (C3bBb). Another inhibitor of the system acting on the terminal pathway is MAC-inhibitory protein (MAC-IP, also known as CD59), which also recognizes host cells, and inhibits the formation of the MAC. A red line towards the target indicates inhibition, whereas a green line indicates augmentation. C4bC2b and C3(H~2~O)Bb are C3 convertases; C4bC2bC3b and C3bBbC3b are C5 convertases. **b** Upon activation of the complement system, C3b is degraded to C3d on the cell surface

Complement-inhibiting therapies that have gone through clinical trials include APL-2, lampalizumab, eculizumab, tesidolumab, CLG561, Zimura and AAVCAGsCD59 (also known as HMR59) (Fig. [1](#Fig1){ref-type="fig"}a). These drugs inhibit the complement system at different levels of the proteolytic cascade.

APL-2 (Apellis Pharmaceuticals, Crestwood, USA), a reformulated version of POT-4, is a cyclic peptide inhibitor of complement component 3 (C3). This drug is currently being tested in a phase II clinical trial (<https://clinicaltrials.gov>, NCT02503332). According to Apellis Pharmaceuticals (<http://www.apellis.com>), this clinical trial has already resulted in a significant reduction in the rate of geographic lesion growth over 12 months. Lampalizumab (Genentech Inc., South San Francisco, CA) is an antigen-binding fragment of a humanized monoclonal antibody that targets complement factor D (FD). The phase II clinical trial for Lampalizumab (MAHALO) has been completed, and yielded promising results with a 20% reduction in atrophy area progression at month 18 for the monthly treated group compared to placebo \[[@CR105]\]. Lampalizumab is currently being evaluated in two phase III clinical trials (SPECTRI and CHROMA, NCT02247531 and NCT02247479, respectively). Recently, Genentech revealed in a press release that SPECTRI did not meet its primary endpoint of reducing mean change in GA lesion area, and that they are expecting the results of CHROMA to be evaluated in November 2017. Eculizumab (Soliris, Alexion Pharmaceuticals, New Haven, USA) is a humanized monoclonal antibody targeting complement 5 (C5). Eculizumab has been approved for the treatment of paroxysmal nocturnal hemoglobinuria. In a phase II clinical trial in AMD (COMPLETE, NCT00935883), systemically administered eculizumab was well-tolerated; however, it did not decrease the growth rate of GA significantly \[[@CR106]\]. Another drug targeting C5 is Zimura (Ophtotech, USA), a chemically synthesized aptamer. This drug is currently in a phase II/III trial (NCT02686658). Tesidolumab (LFG316, Novartis, Basel, Switzerland/MorphoSys, Planegg, Germany) is a human monoclonal antibody also targeting C5. The phase II clinical trial has been completed (NCT015275000); however, the results have not yet been published. Currently, another phase II trial is ongoing which analyzes CLG561 (Novartis, Basel, Switzerland), a fully human antibody Fab that neutralizes properdin, as monotherapy or in combination with tesidolumab (NCT02515942). Finally, the first gene therapy tested for GA treatment is HMR59 (AAVCAGsCD59, Hemera Biosciences Inc., Newton, USA), and its safety is currently being evaluated in a phase I clinical trial (NCT03144999). This therapy consists of a single injection of an adeno-associated virus that transfects the retinal cells, leading to expression of a soluble form of MAC-inhibitory protein (MAC-IP, also named CD59). The potential of gene therapies is further described in Sect. [3.2](#Sec7){ref-type="sec"} of this review.

Complement-inhibiting therapies will presumably be most effective in AMD patients in whom the complement system is most over-activated. Several studies have evaluated levels of complement components and activation fragments, which may represent useful biomarkers for treatment response to complement-inhibiting therapies in AMD. Systemic levels of complement activation fragments such as Ba, Bb, C3a, C3d and C5a and the C3d/C3 ratio, as well as levels of complement components FB and FD seem to be elevated in AMD patients compared to controls \[[@CR107]--[@CR113]\]. Systemic levels of complement component C3 and FI levels, however, appear not to differ between AMD patients and controls \[[@CR108], [@CR109], [@CR111], [@CR113]--[@CR115]\]. FH levels have been reported to be lower in AMD in some studies \[[@CR116], [@CR117]\], but others do not report a difference \[[@CR108], [@CR109], [@CR113], [@CR114], [@CR118]\]. Specific complement levels could therefore be used to identify AMD patients with high levels of complement activity. Nevertheless, a high variability in these complement markers is found within the AMD and control groups, and the levels show a large overlap between cases and controls. Consequently, other markers may be useful as well to predict response. In a recent study including 31 nvAMD patients and 30 controls, aqueous humor differences in Ba and C3a levels were detected, whereas plasma differences were not, probably due to the limited sample size. These results suggest that differences in complement activation levels between patients and controls are larger locally in the eye compared to systemically \[[@CR119]\].

Genetic variants located in or near the *CFH*, *CFI*, *C9*, *C2/CFB*, *C3* and *VNT* genes, encoding components of the complement system, are known to be associated with AMD \[[@CR19]\]. Some of these genetic variants have been shown to affect complement activation levels, and could therefore also be used as biomarkers for complement system activity in AMD. We reviewed the reported associations between common AMD-associated variants and systemic complement system levels in Table [2](#Tab2){ref-type="table"}. SNPs rs12144939 and rs1410996 in the *CFH* gene have been associated with the C3d/C3 ratio, and rs800292 has been associated with Ba and C3d levels and the C3d/C3 ratio \[[@CR111], [@CR120], [@CR121]\]. Genetic variants in the *C2* and *CFB* genes have also been analyzed, and an association with complement activation fragments has been found for rs4151667 (with C3d/C3, Ba and FB), rs641153 (with C3d/C3), and rs9332739 (with Ba) \[[@CR111], [@CR113], [@CR120], [@CR121]\]. SNP rs6795735 and rs2230199 in the *C3* gene seem to influence complement system activation as well. SNP rs6795735 associated with the C3d/C3 ratio, and rs2230199 with levels of C3d, C5a, and the C3d/C3 ratio \[[@CR109], [@CR111], [@CR120], [@CR121]\]. The association of *ARMS2* rs10490924 with complement activation is inconclusive. While one study reported the SNP to influence C5a levels \[[@CR109]\], in another study, it did not \[[@CR111]\], and a third study did not find an association with the C3d/C3 ratio \[[@CR120]\]. In a recent GWAS for complement activation levels, the AMD-associated variant that showed the strongest effect was rs6685931 located in the *CFHR4* gene. Previous associations described for *CFH* and *CFB/C2* were confirmed by the GWAS, while the associations of rs2230199 in *C3* and rs10490924 in *ARMS2* could not be confirmed \[[@CR122]\].Table 2AMD SNPs associated with systemic levels of complement componentsGeneSNPStudyAllele/genotype testedComplement activation measurement(s)Direction of the effect*P* value*CFH*rs12144939Ristau et al. \[[@CR120]\]TC3d/C3−4.6 × 10^−6^rs1410996Ristau et al. \[[@CR120]\]TC3d/C3−10^−4^Reynolds et al. \[[@CR109]\]TT, CT and TTBb, C3a, C5a, FHNArs800292Hecker et al. \[[@CR111]\]GBa+7.1 × 10^−6^Hecker et al. \[[@CR111]\]GC3d+0.0013Ristau et al. \[[@CR120]\]AC3d/C3−0.003Paun et al. \[[@CR121]\]AC3d/C3−0.002Hecker et al. \[[@CR111]\]GFB, FD, FH/FHR-1NA*CHFR4*rs6685931Lores-Motta et al. \[[@CR122]\]CC3d/C3+6.32 × 10^−8^*CFB*rs4151667Hecker et al. \[[@CR111]\]TBa+3.9 × 10^−6^Ristau et al. \[[@CR120]\]AC3d/C3−1.0 × 10^−5^Paun et al. \[[@CR121]\]AC3d/C3−4.1 × 10^−6^Hecker et al. \[[@CR111]\]TFB, FD, FH/FHR-1, C5a, C3dNASmailhodzic et al. \[[@CR113]\]TAFB−\<0.001rs641153Paun et al. \[[@CR121]\]AC3d/C3−0.048Reynolds et al. \[[@CR109]\]CT/TTBb, C3a, C5a, FHNA*C2*rs9332739Hecker et al. \[[@CR111]\]GBa+2 × 10^−6^Hecker et al. \[[@CR111]\]GFB, FD, FH/FHR-1, C5a, C3dNAReynolds et al. \[[@CR109]\]CG/CCBb, C3a, C5a, FHNA*C3*rs6795735Ristau et al. \[[@CR120]\]AC3d/C3+0.04rs2230199Reynolds et al. \[[@CR109]\]CG/GGC5a+0.04Ristau et al. \[[@CR120]\]GC3d/C3+0.04Paun et al. \[[@CR121]\]GC3d/C3+0.035Hecker et al. \[[@CR111]\]CC3d+0.039Hecker et al. \[[@CR111]\]CFB, FD, FH/FHR-1, C5a, BaNAReynolds et al. \[[@CR109]\]CG/GGBb, C3a, FHNA*ARMS2*rs10490924Reynolds et al. \[[@CR109]\]GT/TTC5a+0.02Reynolds et al. \[[@CR109]\]GT/TTBb, C3a, FHNAHecker et al. \[[@CR111]\]NSFB, FD, FH/FHR-1, C5a, Ba, C3dNA*AMD* age-related macular degeneration, *NA* not associated, *NS* not specified, *SNP* single-nucleotide polymorphism

Recently, rare coding variants in the *CFH*, *CFI*, *C3* and *C9* genes have been described in AMD patients, and have also been shown to have an effect on systemic levels of complement components. Carriers of *CFH* Arg127His \[[@CR123]\], Arg175Pro \[[@CR124]\] and Cys192Phe \[[@CR125]\] variants showed reduced FH levels. In carriers of *CFI* Gly119Arg \[[@CR115]\], Gly188Ala \[[@CR115]\] and Ala240Gly variants \[[@CR126]\], reduced FI levels were observed. Carriers of the *C9* variant Arg95Ter showed C9 levels below the detection level \[[@CR127]\], and in carriers of Pro167Ser \[[@CR128]\], C9 levels were elevated. Other rare variants did not show an effect on systemic levels individually, but a functional effect on complement activation has been described. The effect of these rare variants has been recently reviewed by Geerlings and colleagues \[[@CR129]\]. Rare coding variants, in particular those showing an effect on complement activation, may therefore also be useful to select patients for complement-inhibiting treatments.

Besides genetic biomarkers, other biomarkers that associate with AMD and complement activity could also be used to identify AMD patients with an over-activated complement system. Other reported factors include low systemic triglyceride levels and high body mass index (BMI) \[[@CR120]\].

Gene- and Cell-Based Therapies {#Sec7}
------------------------------

The high and increasing prevalence of AMD together with the limited therapeutic options have boosted research for new therapies \[[@CR12]\]. These new therapeutic strategies make use of the latest technological advances including gene therapy and stem cells. In this section, we review gene- and cell-based therapies that have been or are currently being tested in clinical trials.

### Gene Therapy {#Sec8}

Gene therapy introduces specific genetic material into the patient's cells, usually by means of a viral vector. The successful example of gene replacement therapy for the treatment of a monogenic retinal disease, Leber congenital amaurosis \[[@CR130]\], motivated the development of gene therapy clinical trials for AMD. In AMD, the focus is on promoting the expression of a therapeutic protein in RPE cells. Viral vectors are delivered intravitreally or subretinally. An overview of gene therapy clinical trials for AMD is presented in Table [3](#Tab3){ref-type="table"}.Table 3Gene therapy and stem cell-based therapies for AMD in clinical trialsDrugGene expressedTargetClinical phaseResultsReferencesClinicaltrials.gov identifierFunding (clinicaltrials.gov)Gene therapy AdGVPEDF.11DPEDFNV AMDPhase ICompleted: No serious adverse events and no dose-limiting toxicities; transient intraocular inflammation occurred in 25% of patientsCampochiaro et al. \[[@CR132]\]NCT00109499GenVec AAV2-sFLT01sFLT101 (domain 2 of Flt-1 linked to human IgG1-Fc)NV AMDPhase ICompleted: safe and well-tolerated at all doses; potential effect of baseline anti-AAV2 serum antibodies and transgene expressionHeier et al. \[[@CR134]\]NCT01024998Genzyme, a Sanofi Company OXB-201 (RetinoStat)Angiostatin and endostatinNV AMDPhase ICompleted: well-tolerated with no dose-limiting toxicities; reduction in leakage for 71% of participants; reduction in fluid in 1 patientCampochiaro et al. \[[@CR138]\]NCT01301443Oxford BioMedicaPhase IOngoing (long-term safety---15 years)NCT01678872Oxford BioMedica RGX-314sAnti-VEGF proteinNV AMDPhase IOngoingNCT03066258Regenxbio Inc. AAVCAGsCD59 or HMR59CD59GA AMDPhase IOngoingNCT03144999Hemera Biosciences rAAV.sFLT-1sFLT1NV AMDPhase ICompleted: safe and well-tolerated after 36 monthsRakoczy et al. \[[@CR164]\]; Constable et al. \[[@CR165]\]NCT01494805Lions Eye Institute, Perth, Western AustraliaPhase IIPhase IIa completed: smaller improvement than ranibizumab aloneConstable et al. \[[@CR135]\]NCT01494805Lions Eye Institute, Perth, Western AustraliaType of therapyTargetClinical phaseResultsReferenceClinicaltrials.gov identifier/UMIN_CTR identifierFunding (clinicaltrials.gov)Stem cell therapy Autologous BMSCsGA AMDPhase I/IIUnknown (estimated completion date 2015)NCT02016508Al-Azhar University Autologous BMSCsNV and GA AMDPhase I/IICompletedNCT01518127University of Sao Paulo hCNSSCGA AMDPhase I/IICompleted: long-term safety assessment terminatedNCT01632527StemCells, Inc. hESC-RPEGA AMDPhase I/IICompleted: safe and possible activity of the cellsSchwartz et al. \[[@CR140], [@CR141]\]NCT01344993Astellas Institute of Regenerative Medicine Human umbilical tissue-derived cells (Palucorcel, CNTO-2476)GA AMDPhase I/IIaCompleted: subretinal delivery associated with perforations and detachment; well-tolerated; may lead to VA improvementsHo et al. \[[@CR166]\]NCT01226628Janssen Research & Development, LLC Autologous BMSCsGA AMDPhase ICompleted: well-toleratedPark et al. \[[@CR78]\]NCT01736059University of California, Davis hESC-RPE (OpRegen)GA AMDPhase I/IIOngoingNCT02286089Cell Cure Neurosciences Ltd. Somatic cell nuclear transfer hESC-RPEGA AMDPhase IOngoingNCT03305029CHA University hESC-RPEGA AMDEarly phase IOngoingNCT03046407Chinese Academy of Sciences hESC-RPEGA AMDEarly phase IOngoingNCT02755428Chinese Academy of Sciences hESC-RPE in suspension and seeded on a substrateNV and GA AMDPhase I/IIOngoingNCT02903576Federal University of Sao Paulo Autologous BMSCsAMDNot specifiedOngoingNCT03011541MD Stem Cells Autologous iPSC-RPEGA AMDProduction of the cellsOngoingNCT02464956Moorfields Eye Hospital NHS Foundation Trust hESC-RPE (Pf-05206388)NV AMDPhase IOngoing (long-term safety, 4-year follow-up)NCT03102138Pfizer hESC-RPE on a parylene membrane (CPCB-RPE)GA AMDPhase I/IIOngoingNCT02590692Regenerative Patch Technologies, LLC Autologous BMSCsAMDNot specifiedOngoingNCT01920867Retina Associates of South Florida hESC-RPEAMDPhase IOngoingNCT02749734Southwest Hospital, China hESC-RPEGA AMDPhase I/IIOngoing (long-term safety and tolerability)NCT02463344Astellas Institute for Regenerative Medicine Somatic cell nuclear transfer hESC-RPEGA AMDPhase I/IIaOngoing (preliminary results: safe and tolerated; 2 patients included; 1 patient gained VA and the other maintained VA)Song et al. \[[@CR142]\]NCT01674829CHA Biotech CO., Ltd hESC-RPE (ASP7317)GA AMDPhase Ib/IINot open yetNCT03178149Astellas Institute for Regenerative Medicine hESC-RPEGA AMDPhase I/IINot open yet (evaluation of long-term safety)NCT03167203Astellas Institute for Regenerative Medicine Autologous fibroblast iPSC-RPE sheetNV AMDPhase I/IICompleted: patient 1 after 1 year the cell sheet appears to be safe and remains intact, VA maintained. Patient 2 did not receive therapy due to concerns about genetic changes in the iPSCs and iPSC-derived RPEMandai et al. \[[@CR143]\]UMIN000011929RIKENAllogenic HLA-matched iPSC-RPENV AMDPhase IOngoingUnknownRIKEN*AMD* age-related macular degeneration, *BMSCs* bone marrow-derived stem cells, *CPCB-RPE* human embryonic stem cell-derived retinal pigment epithelial cells seeded on a polymeric substrate, *GA AMD* advanced geographic atrophy AMD, *hCNSSC* human central nervous system stem cells, *hESC-RPE* human embryonic stem cell-derived retinal pigmented epithelial cells, *HLA* human leukocyte antigen, *iPSC* induced pluripotent stem cell, *iPSC-RPE* induced pluripotent stem cell-derived retinal pigmented epithelial cells, *NV AMD* advanced neovascular AMD, *RPE* retinal pigmented epithelial, *VA* visual acuity

AAVCAGsCD59, discussed in Sect. [3.1](#Sec6){ref-type="sec"}, is the only gene therapy trial targeting the complement system which is currently being tested for GA, and inhibits MAC formation through CD59 expression. Other gene therapy trials target the neovascular form of AMD. AdGVPEDF.11D leads to expression of pigment epithelium-derived factor (PEDF), an anti-angiogenic protein that counteracts the effects of VEGF in the CNV process \[[@CR131]\]. This therapy has not been further evaluated since the results of the phase I trial in 2006 \[[@CR132]\]. AAV2-sFLT01 and rAAV.sFLT-1 both express soluble vascular endothelial growth factor receptor 1 (sFLT-1), an antagonist for VEGF \[[@CR133]\]. The results of the phase I trial of AAV2-sFLT01 have recently been published with positive safety data and toleration of the drug after 3 years \[[@CR134]\]. rAAV.sFLT-1 has already been evaluated in phase IIa; however, the control and the treatment groups performed worse than ranibizumab alone group \[[@CR135]\]. OXB-201, also known as RetinoStat, leads to the expression of the anti-angiogenic proteolytic products angiostatin and endostatin \[[@CR136], [@CR137]\]. Phase I has already been completed, and no adverse events were observed \[[@CR138]\]; therefore, long-term safety studies are ongoing. Finally, RGX-314 encodes for a soluble anti-VEGF protein and is currently being evaluated in phase I clinical trials.

Anti-angiogenic factors delivered using gene therapy might show also a variability in response as it has been described for the currently used anti-VEGF antibodies. Therefore, pharmacogenetic associations found for anti-VEGF therapy might be analyzed in clinical trials of gene therapy for nvAMD.

In addition, research on gene therapy for supplementation of FH is currently ongoing \[[@CR139]\], and supplementation therapy for FI might be useful, as carriers of rare variants show reduced FI levels. For this particular therapy, patient selection based on genotype will be required. Carriers of rare variants in *CFH* and *CFI* known to have strong effects on the protein function or levels would be the best candidates for inclusion in clinical trials.

### Stem Cell Therapy {#Sec9}

Another novel therapeutic approach with great potential for AMD is the use of stem cells, which are reprogrammed to the cell type of interest and transplanted to the patient. Transplantation of RPE cells derived from stem cells for AMD treatment is currently being evaluated in several clinical trials (Table [3](#Tab3){ref-type="table"}). The first clinical trial started in 2011 and involved human embryonic stem cell (hESC)-derived RPE cells (NCT01344993). The therapy was found to be safe with no tumorigenicity and showed potential effectiveness \[[@CR140], [@CR141]\]. These results have been followed up with a new improved therapy (NCT03178149, NCT03167203) that is currently being evaluated by developers in the Astellas Institute for Regenerative Medicine. Other ongoing clinical trials are also based on hESC-derived RPE; however, their use requires immunosuppressive treatment, bearing risks \[[@CR142]\] and raising ethical concerns due to the use of embryonic cells. More recently, the use of induced pluripotent stem cells (iPSC) has begun to be explored. One of the key benefits of this therapy is that immunosuppression is not needed, as the source is the patient's own somatic cells. However, it implies an increased cost of therapy, as it needs to be developed for each patient individually. The first clinical trial with iPSC (<http://www.umin.ac.jp>, UMIN000011929) has recently been performed at the Japanese research institute RIKEN, where a 70-year-old AMD patient received a transplant of a sheet of autologous iPSC-RPE. After 1 year of follow-up, no adverse events had been detected and the patient's vision remained stable \[[@CR143]\]. However, this trial has been stopped for the second patient enrolled, because of genetic changes found in the generated iPSC \[[@CR144]\]. This group has recently shifted their approach towards the use of allogenic human leukocyte antigen (HLA)-matched iPSC-RPE, and in March 2017, it was announced that the first patient received allogenic iPSC-RPE \[[@CR145]\]. This approach would be less costly and would avoid the effect of the genetic AMD-risk variants that the patients carry. Nevertheless, it would most likely imply the use of immunosuppressant drugs. Contrary to these promising results of the group in RIKEN, in a back-to-back publication, it was reported that autologous adipose tissue-derived stem cells were administered bilaterally to three AMD patients in a stem cell clinic, leading to a severe visual loss in all cases \[[@CR146]\]. These disastrous events highlight that even though stem cell therapy holds promise, strict regulations should be applied before any treatment with stem cells is administered to patients.

RPE stem cell therapy might be the best therapeutic option for advanced cases in which there is RPE degeneration; however, it involves the transplantation of new cells in a diseased environment, and as such, the survival of the new cells may depend on inflammation and oxidative stress levels in the host environment. The C3/C3 ratio, as a marker of complement activation, malondialdehyde levels, as a marker of lipid peroxidation, and homocysteine levels, an oxidative stress marker, are molecular biomarkers for AMD that may correlate with the success of such therapies \[[@CR147]\]. Moreover, autologous iPSC might not be the best option for AMD patients carrying highly penetrant genetic variants, and hESC or HLA-matched iPSC may be more effective in these patients.

Discussion and Future Perspectives {#Sec10}
==================================

The use of genetic biomarkers to advise patients with AMD on the use of dietary supplements is a topic of intense debate that has not yet been settled. Based on the recent findings of Assel at al. \[[@CR35]\], dietary supplementation for slowing down disease progression should be prescribed to any AMD patient, irrespective of *CFH* and *ARMS2* genotypes, but this is contradicted by a more recent study by Vavvas et al. on an extended dataset, which concluded that the use of the AREDS formulation should be based on patient-specific genotypes \[[@CR36]\]. However, the findings in all studies of this debate are based on the AREDS dataset only, and future independent prospective studies would be beneficial to draw a definite conclusion, as well as to further investigate if other genetic variants may interact with the formulation.

In regard to the pharmacogenetics of anti-VEGF treatment, results are not conclusive yet; therefore, these results are not yet helpful for precision medicine. Nonetheless, recurrent results from multiple studies suggest that SNP rs1061170 in *CFH* may influence response to treatment. This finding could potentially be explained by the effect of this SNP on faster disease progression \[[@CR148]\]. However, this association was not detected in the analyses from the CATT and IVAN clinical trials \[[@CR71], [@CR72]\], therefore warranting further investigation. Additionally, the magnitude of the effect of this variant might not reach clinical utility and would need to be combined with other genetic variants or clinical parameters. Other compelling candidate genetic variants for further evaluation include *ARMS2* rs10490924, *VEGFA* rs833061, *OR52B4* rs4910623, *NRP1* rs2070296, *APOE* ε4 allele, *IL8* rs4073 and *PEDF* rs1136287. *OR52B4* rs4910623 was identified in a GWAS using pooled DNA, indicating that a GWAS with single-patient genotyping and increased statistical power may reveal new associated variants. Additionally, rare variants potentially bearing larger effects, and therefore clinical relevance, have not been evaluated yet \[[@CR149]\].

A key problem remains that the definition of response is not consistently defined across cohorts. In 2015, in order to provide a consensus, a committee of retinal specialists proposed definitions of good, poor and non-response based on a combination of anatomical and functional measurements \[[@CR150]\]. These definitions should be adopted by researchers in future studies, which would enable study comparisons in a standardized framework. Analysis of the different outcome measures used for these definitions as continuous variables would be also highly valuable. Additionally, prospective studies with sufficient statistical power would allow sub-phenotype analyses, which may reveal new or stronger associations.

Biomarkers identified in aqueous humor samples are VEGF and IL-6; however, these samples are not taken routinely. IL-6, IL-17, TNF-α and C3a have been identified as potential systemic biomarkers, and therefore could be readily measured before treatment. Moreover, as baseline VEGF has been associated with response in aqueous humor samples, it could be further investigated as a systemic biomarker. Recent studies suggest that anti-VEGF treatment may lead to an increased risk of GA development \[[@CR151]\]. Therefore, screening of genetic markers together with other biomarkers and clinical parameters for effective anti-VEGF therapy planning may become necessary. Clinical trials would be albeit needed before the screening of these biomarkers can be implemented in the clinic.

Complement therapies are being developed for the treatment of GA, and biomarkers for complement activity could be useful to identify the most suitable AMD patients for these therapies. Systemic levels of complement activation fragments such as the C3d/C3 ratio can be used as biomarkers for complement activity in AMD. Moreover, levels of the specific target of each drug could be a useful biomarker. Therapies undergoing trials are targeting FD, C3, properdin and C5. FD levels have been seen to be higher in AMD patients compared to controls, and therefore, they could be a useful biomarker for this specific therapy. C3 levels do not differ between AMD and controls, and properdin and C5 levels have not been evaluated. A comprehensive analysis of the complement system components in AMD could identify new potential biomarkers. However, how systemic measurements reflect the local situation at the disease site needs to be further investigated.

Additionally, AMD-associated SNPs that associate with systemic complement activation can be used as robust biomarkers. The added value of these genetic biomarkers is that as they are associated with disease risk, they most probably reflect complement activity in the eye, whereas the overall systemic complement activation may not always be representative of the conditions at the disease site. rs12144939, rs1410996 and rs800292 in *CFH*, rs4151667, rs641153 and rs9332739 in *C2/CFB*, and rs6795735 and rs2230199 in *C3* have been reported to be associated with systemic complement activation levels. In a recent GWAS for complement activation levels, the AMD-associated variant that showed the strongest effect was rs6685931 located in the *CFHR4* gene. Moreover, rare variants in the *CFH* gene (Arg127His, Arg175Pro and Cys192Phe), in the *CFI* gene (Gly119Arg, Gly188Ala and Ala240Gly) and in the *C9* gene (Arg95Ter and Pro167Ser) have been associated with altered FH, FI and C9 levels, respectively. However, the magnitude of the effects of these genetic variants at the disease site still needs to be evaluated. Additionally, other variants for which a systemic effect has not been detected most probably have a local effect. Consequently, genetic studies using aqueous humor samples are greatly needed. The identified genetic factors may be used alongside systemic complement activation levels and other environmental factors such as BMI and triglyceride levels to identify AMD patients with a burden of the complement system in their AMD disease. Well-powered replication studies are needed, as well as comprehensive genetic studies of the effect of all the 52 independently AMD-associated variants on systemic complement activation levels \[[@CR19]\].

Other new therapeutic approaches will most probably not work in the same manner for all AMD patients. As a consequence, a deeper molecular characterization of AMD patients including proteomics, metabolomics, transcriptomics and genomics is essential. Such in-depth characterization will help to understand the molecular drivers in each individual patient and to develop pharmacomics, paving the way towards precision medicine in AMD.
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